These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27335026)

  • 1. TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer.
    Ferraro D; Goldstein D; O'Connell RL; Zalcberg JR; Sjoquist KM; Tebbutt NC; Grimison P; McLachlan S; Lipton LL; Vasey P; Gebski VJ; Aiken C; Cronk M; Ng S; Karapetis CS; Shannon J;
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):361-7. PubMed ID: 27335026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
    Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
    Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
    Hezel AF; Noel MS; Allen JN; Abrams TA; Yurgelun M; Faris JE; Goyal L; Clark JW; Blaszkowsky LS; Murphy JE; Zheng H; Khorana AA; Connolly GC; Hyrien O; Baran A; Herr M; Ng K; Sheehan S; Harris DJ; Regan E; Borger DR; Iafrate AJ; Fuchs C; Ryan DP; Zhu AX
    Br J Cancer; 2014 Jul; 111(3):430-6. PubMed ID: 24960403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
    Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
    Jensen LH; Lindebjerg J; Ploen J; Hansen TF; Jakobsen A
    Ann Oncol; 2012 Sep; 23(9):2341-2346. PubMed ID: 22367707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations.
    Amin NEL; Hansen TF; Fernebro E; Ploen J; Eberhard J; Lindebjerg J; Jensen LH
    Int J Cancer; 2021 Jul; 149(1):119-126. PubMed ID: 33561312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.
    Sohal DP; Mykulowycz K; Uehara T; Teitelbaum UR; Damjanov N; Giantonio BJ; Carberry M; Wissel P; Jacobs-Small M; O'Dwyer PJ; Sepulveda A; Sun W
    Ann Oncol; 2013 Dec; 24(12):3061-5. PubMed ID: 24146220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
    Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K
    Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
    Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
    Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
    Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
    Goldstein D; Gainford MC; Brown C; Tebbutt N; Ackland SP; van Hazel G; Jefford M; Abdi E; Selva-Nayagam S; Gebski V; Miller D; Shannon J
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):519-25. PubMed ID: 20461378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
    Valle JW; Wasan H; Lopes A; Backen AC; Palmer DH; Morris K; Duggan M; Cunningham D; Anthoney DA; Corrie P; Madhusudan S; Maraveyas A; Ross PJ; Waters JS; Steward WP; Rees C; Beare S; Dive C; Bridgewater JA
    Lancet Oncol; 2015 Aug; 16(8):967-78. PubMed ID: 26179201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
    Rubovszky G; Láng I; Ganofszky E; Horváth Z; Juhos E; Nagy T; Szabó E; Szentirmay Z; Budai B; Hitre E
    Eur J Cancer; 2013 Dec; 49(18):3806-12. PubMed ID: 24007821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
    Yardley DA; Ward PJ; Daniel BR; Eakle JF; Lamar RE; Lane CM; Hainsworth JD
    Clin Breast Cancer; 2016 Oct; 16(5):349-355. PubMed ID: 27340049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
    Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
    Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
    BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
    Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
    Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
    Kim RD; Alberts SR; Peña C; Genvresse I; Ajavon-Hartmann A; Xia C; Kelly A; Grilley-Olson JE
    Br J Cancer; 2018 Feb; 118(4):462-470. PubMed ID: 29348486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
    Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
    Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.